A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy

Clinical Therapeutics

Volumn 25, Issue 5, 2003, Pages 1420-1428

  Wright, Padraig ^a,b   Meehan, Karena ^b,c   Birkett, Martin ^a   Lindborg, Stacy R ^a   Taylor, Cindy C ^a   Morris, Philip ^d   Breier, Alan ^a  

^a ELI LILLY AND COMPANY   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d GOLD COAST UNIVERSITY HOSPITAL   (Australia)

Author keywords

Agitation; Antipsychotic; Haloperidol; Intramuscular; Olanzapine; Schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE; PLACEBO;

ADULT; AGITATION; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITAL PATIENT; HUMAN; INTOXICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0037607491     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80129-7     Document Type: Article

References (15)

1. Chouinard G, Annable L, Turnier L, et al. A double-blind randomized clinical trial of rapid tranquilization with IM clonazepam and IM haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatry. 1993;38(Suppl 4):S114-S121.
2. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001;62:153-157.
3. Brook S, Lucey JV, Gunn KP, for the Ziprasidone IM Study Group. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry. 2000;61:933-941.
4. Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry. 1991;52:177-180.
5. Tollefson GD, Beasley CM Jr, Tran P, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465.
6. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.
7. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry. 2000;61(Suppl 3):16-21.
8. Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J Clin Psychiatry. 1997;58(Suppl 10):63-72.
9. Still DJ, Dorson PG, Crismon ML, Pousson C. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv. 1996;47:1382-1384.
10. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001;158:1149-1151.
11. Kay SR, Sevy S. Pyramidical model of schizophrenia. Schizophr Bull. 1990;16:537-545.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
13. Wright P, Kiesler G, Mitchell M, et al. Safety and efficacy of intramuscular (IM) olanzapine in patients with acute nonorganic psychosis. Schizophr Res. 1999;36:318. Abstract.
14. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
15. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Stand Suppl. 1970;212:11-19.